CARGO Therapeutics, Inc. Common Stock (CRGX NASDAQ) stock market data APIs
$4.165
-0.07(-1.7%)
as of March 14, 2025
CARGO Therapeutics, Inc. Common Stock Financial Data Overview
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Prev. Close
4.2344
Open
4.165
High
4.3174
Low
4.2082
52 wk Range
3-32.79
Market Cap
194 M
Shares Outstanding
46 052 K
EPS
-0.95
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CARGO Therapeutics, Inc. Common Stock data using free add-ons & libraries
Get CARGO Therapeutics, Inc. Common Stock Fundamental Data
CARGO Therapeutics, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -184 712 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-12-31
- EPS/Forecast: -0.9458
Get CARGO Therapeutics, Inc. Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CARGO Therapeutics, Inc. Common Stock News
New
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients.CARGO to ...
Undiscovered Stocks on the Verge of a Breakout: 3 Names to Know Now
Many investors steer clear of limelight stocks. These ideas might already be overvalued and often aren’t the breakout stocks that can deliver significant returns. On the other hand, stocks that are...
3 New Stock Listings That Can Deliver Multibagger Returns
The U.S. IPO market has been relatively sluggish this year with 149 IPOs. At the same time, disappointing stories outnumbered businesses that created value. However, amidst the depression are several ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
